{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:23:24Z","timestamp":1761294204137,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Advanced therapy-refractory solid tumors bear a dismal prognosis and constitute a major challenge in offering effective treatment strategies. In this real-world retrospective analysis of our precision medicine platform MONDTI, we describe the molecular profile of 554 patients diagnosed with 17 different types of advanced solid tumors after failure of all standard treatment options. In 304 cases (54.9% of all patients), a molecular-driven targeted therapy approach could be recommended, with a recommendation rate above 50% in 12 tumor entities. The three highest rates for therapy recommendation per tumor classification were observed in urologic malignancies (90.0%), mesothelioma (78.6%), and male reproductive cancers (71.4%). Tumor type (p = 0.46), expression of p-mTOR (p = 0.011), expression of EGFR (p = 0.046), and expression of PD-L1 (p = 0.023) had a significant impact on the targeted therapy recommendation rate. Therapy recommendations were significantly more often issued for men (p = 0.015) due to gender-specific differences in the molecular profiles of patients with head and neck cancer and malignant mesothelioma. This analysis demonstrates that precision medicine was feasible and provided the basis for molecular-driven therapy recommendations in patients with advanced therapy refractory solid tumors.<\/jats:p>","DOI":"10.3390\/jpm10040188","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T08:59:28Z","timestamp":1603443568000},"page":"188","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeted Therapy Recommendations for Therapy Refractory Solid Tumors\u2014Data from the Real-World Precision Medicine Platform MONDTI"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-6498","authenticated-orcid":false,"given":"Hossein","family":"Taghizadeh","sequence":"first","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Unseld","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-930X","authenticated-orcid":false,"given":"Martina","family":"Spalt","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3017-8240","authenticated-orcid":false,"given":"Robert M.","family":"Mader","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-078X","authenticated-orcid":false,"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"},{"name":"Clinical Institute of Pathology, Medical University Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Fuereder","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sibilia","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"},{"name":"Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mir Alireza","family":"Hoda","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"},{"name":"Department of Surgery, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6760-949X","authenticated-orcid":false,"given":"Stefanie","family":"Aust","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"},{"name":"Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Polterauer","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"},{"name":"Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Lamm","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3520-4105","authenticated-orcid":false,"given":"Kautzky-Willer","family":"A.","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Medicine III, Gender Medicine Unit, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Cancer Center Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T.F., Al Lami, F.H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., and Amini, E. (2018). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol., 4, 1553\u20131568.","DOI":"10.1200\/JCO.2018.36.15_suppl.1568"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1758834011427927","article-title":"Erlotinib in the treatment of advanced non-small cell lung cancer: An update for clinicians","volume":"4","author":"Wang","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11523-015-0358-9","article-title":"Gefitinib: A review of its use in adults with advanced non-small cell lung cancer","volume":"10","author":"Dhillon","year":"2015","journal-title":"Target Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Stephenson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"942","DOI":"10.18632\/oncotarget.26604","article-title":"Results of the extended analysis for cancer treatment (EXACT) trial: A prospective translational study evaluating individualized treatment regimens in oncology","volume":"10","author":"Prager","year":"2019","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-1836","article-title":"Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib \u00b1 onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit","volume":"20","author":"Koeppen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gelsomino, F., Casadei-Gardini, A., Caputo, F., Rossi, G., Bertolini, F., Petrachi, T., Spallanzani, A., Pettorelli, E., Kaleci, S., and Luppi, G. (2020). mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus. Cancers, 12.","DOI":"10.3390\/cancers12051201"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, S., Kong, Y., Si, L., Chi, Z., Cui, C., Sheng, X., and Guo, J. (2014). Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-376"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000055397","article-title":"Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials","volume":"61","author":"Baselga","year":"2001","journal-title":"Oncology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/2193-1801-3-111","article-title":"Response to imatinib as a function of target kinase expression in recurrent glioblastoma","volume":"3","author":"Hassler","year":"2014","journal-title":"SpringerPlus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing--when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/0008-5472.CAN-15-3024","article-title":"Tumor Heterogeneity\u2014A \u2018Contemporary Concept\u2019 Founded on Historical Insights and Predictions","volume":"76","author":"Welch","year":"2016","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"33358","DOI":"10.18632\/oncotarget.5188","article-title":"The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: Prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: The Princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","article-title":"Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01\/UNICANCER)","volume":"15","author":"Andre","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Delord","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis","volume":"40","author":"Bebawy","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e000113","DOI":"10.1136\/esmoopen-2016-000113","article-title":"I-SPY 2: Optimising cancer drug development in the 21st century","volume":"1","author":"Bartsch","year":"2016","journal-title":"ESMO Open"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/10\/4\/188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:52Z","timestamp":1760178412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/10\/4\/188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jpm10040188"],"URL":"https:\/\/doi.org\/10.3390\/jpm10040188","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}